|Bid||87.16 x 20000|
|Ask||87.45 x 20000|
|Day's Range||87.01 - 87.01|
|52 Week Range||53.60 - 87.01|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||13.25|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene Corp. (CELG) closes, the company is making some big changes at the top. Shareholders are keeping their fingers crossed that the union and the management shake-up will be just what the company needs to boost its shares. Owners of the stock might be more concerned, though, that the company moves are just more window dressing.
Bristol-Myers stock is cheap, but investors are sitting on the sidelines ahead of the Celgene merger, an analyst said Wednesday. The deal is now expected to close late in the third quarter.
What to Expect from Bristol-Myers Squibb after CELG Acquisition(Continued from Prior Part)Immunology portfolioBristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) is expected to make the combined company a top-five player in the I&I
What to Expect from Bristol-Myers Squibb after CELG AcquisitionBristol-Myers Squibb and Celgene On April 12, Bristol-Myers Squibb (BMY) issued a press release announcing shareholder approval of its proposed acquisition of Celgene. The company
What to Expect from Bristol-Myers Squibb after CELG Acquisition(Continued from Prior Part)Stock price movements and valuationOn June 3, Bristol-Myers Squibb (BMY) closed at $46.12, 1.65% higher than the previous close, 4.11% higher than its 52-week
Credit Suisse analyst Vamil Divan says investors see an upside in the company’s merger with Celgene, but as yet have too many questions.
Shares of biotech company Celgene rose Tuesday after the FDA accepted its application for an Acceleron Pharma-partnered anemia treatment in beta thalassemia and some blood cancers.
Now that the controversial acquisition of Celgene by Bristol-Myers Squibb for around $74 billion seems all but a done deal, analysts are taking a hard look at the nascent Frankenstein’s monster of a drug company—and throwing their hands in the air.
Ted Samuels paid $236,440 for 5,000 shares last week. It’s the first open-market purchase of Bristol-Myers stock by an insider in a year.
For these mental hacks, David Gardner tapped the wisdom of four authors and one alien hive mind. For the stocks, he looked to the Information Age for inspiration.
While value investors continue to read through Seth Klarman (Trades, Portfolio)'s most recent partnership letter, others are tracking his latest filings to see what the guru has deemed worthy of buying. Warning! GuruFocus has detected 3 Warning Sign with CDAY.
Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst.
Bristol-Myers Squibb's (BMY) move to raise close to $20 billion in debt to acquire Celgene (CELG) looks dangerous, but years from now it may be considered a savvy move. True, the huge aggregate number of $58 billion in combined debt between the two companies certainly doesn't look all that flattering, especially in the context of threats by all three credit rating agencies - Moody's, Fitch and S&P Global Ratings - to downgrade the company's credit rating. The ratings agencies correctly cite total debt at 4x earnings, and that makes the corporate bond markets justifiably jittery.
Joining Yahoo Finance's Jen Rogers and Myles Udland is Jared Blikre to break down the week's market action in the S&P 500, its 11 sectors (where tech is leading the year again), as well as the weekly winners in the Nasdaq 100 — all with the help of our new YFi Interactive touch screen.